array(3) { ["company_details"]=> array(13) { ["name"]=> string(13) "Pharming B.V." ["slug"]=> string(20) "00474-nl-pharming-bv" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/6f06b060-b806-43f2-addd-a605083bf776" ["description"]=> string(987) "Pharming is a global biopharmaceutical company that develops and commercializes innovative protein replacement therapies and precision medicines for rare diseases. They are committed to being a sustainable partner for all stakeholder groups, including patients, healthcare professionals, employees, and shareholders. Pharming is headquartered in Leiden, the Netherlands, with its U.S. headquarters in Warren, New Jersey. They are listed on the Amsterdam Euronext and Nasdaq exchanges. Their vision is to become the leading global rare disease company and their mission is to bring solutions to unserved rare disease patients through drug development and commercialization. They aim to transform their pipeline to include multiple commercialized products in multiple geographies and to expand their technology portfolio. The company culture at Pharming emphasizes teamwork, self-development, and results orientation. They participate in investor conferences and provide financial updates." ["address_street"]=> string(12) "Darwinweg 24" ["address_place"]=> string(6) "Leiden" ["address_region"]=> NULL ["founding_date"]=> NULL ["website_domain"]=> string(12) "pharming.com" ["website_url"]=> string(24) "https://www.pharming.com" ["industry_codes"]=> array(1) { [0]=> string(75) "Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified" } ["employee_count"]=> NULL ["article_count"]=> int(54) } ["articles"]=> array(1) { [0]=> array(7) { ["title_en"]=> string(118) "Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan" ["snippet_en"]=> string(296) "LEIDEN, The Netherlands, Aug.9, 2023 /PRNewswire/ -- Pharming Group N.V.( `` Pharming '' or `` the Company '')( EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled in its Phase III clinical trial in Japan evaluating leniolisib for the treatment of activated" ["url"]=> string(179) "https://www.morningstar.com/news/pr-newswire/20230809cl78010/pharming-announces-first-patient-enrolled-in-phase-iii-clinical-trial-of-leniolisib-for-the-treatment-of-apds-in-japan" ["image_url"]=> NULL ["source"]=> string(15) "morningstar.com" ["publication_date"]=> NULL ["categories"]=> array(1) { [0]=> string(5) "R & D" } } } ["category_annotations"]=> array(28) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(12) } [1]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(8) } [2]=> array(2) { ["name"]=> string(10) "Insolvency" ["count"]=> int(4) } [3]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(4) } [4]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(3) } [5]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(3) } [6]=> array(2) { ["name"]=> string(9) "Investors" ["count"]=> int(2) } [7]=> array(2) { ["name"]=> string(21) "Financial Performance" ["count"]=> int(2) } [8]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(2) } [9]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(1) } [10]=> array(2) { ["name"]=> string(10) "Executives" ["count"]=> int(1) } [11]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(1) } [12]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(1) } [13]=> array(2) { ["name"]=> string(24) "Government Interventions" ["count"]=> int(1) } [14]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(1) } [15]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(1) } [16]=> array(2) { ["name"]=> string(21) "Shareholders Feedback" ["count"]=> int(1) } [17]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(1) } [18]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(1) } [19]=> array(2) { ["name"]=> string(9) "Valuation" ["count"]=> int(1) } [20]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(1) } [21]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(1) } [22]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(1) } [23]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(1) } [24]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(1) } [25]=> array(2) { ["name"]=> string(5) "Debts" ["count"]=> int(1) } [26]=> array(2) { ["name"]=> string(19) "Economic Conditions" ["count"]=> int(1) } [27]=> array(2) { ["name"]=> string(7) "Economy" ["count"]=> int(1) } } } 00474-nl-pharming-bv